

SJVIA Board Meeting: Consultant's Report - EmpiRx 2021 Utilization

2021 Overall Plan Spend

- SJVIA's total plan cost increased in 2021 by 6.7% from 2020 to \$20,472,962
 - Tulare: \$8,397,297 in Plan Cost
 - Fresno: \$12,075,665 in Plan Cost
- The increase in plan spend can be attributed to utilization increasing, as well as inflation.

2021 Channel Summary

- Majority of the SJVIA members continue to fill scripts at retail.
 - Retail scripts account for 98.61% of plan spend.
 - Majority of scripts are being filled in the retail generic or retail90 generic channel.

2021 Generic Dispensing

- The Generic Dispensing Rate Continues to trend well for SJVIA in all channels.
 - Although the GDR trends well, it did decrease slightly for Retail GDR in 2021.
 - 2021 Retail GDR: 81.42%
 - 2020: 84.49%
 - 2021 Retail90 GDR: 88.93%
 - 2020: 88.25%
 - 2021 Mail GDR: 87.12%
 - 2020: 83.63%

2021 Specialty Plan Spend

- 2021 specialty plan spend increased compared to 2020.
 - The spend shift can be mostly attributed to the specialty channel seeing a significant increase in utilization in 2021.
 - Specialty Plan Costs in 2021: \$8,044,018 (39.29% of plan spend)
 - Specialty Plan cost in 2020: \$6,127,050
 - Specialty claims volume increased with new utilization in 2021.
 - 2,166 Scripts filed in 2021.
 - 153 additional scripts compared to scripts filled in 2020
 - 2,013 Scripts filled in 2020
 - SJVIA specialty plan costs trends above the EmpiRx BOB national average range (30%-35%).

Top Clinical Cost Drivers by Therapeutic Class

- ANALGESICS - ANTI-INFLAMMATORY
- ANTIDIABETICS
- DERMATOLOGICALS
- ANTINEOPLATICS AND ADJUNCTIVE THERAPIES
- RESPIRATORY AGENTS- MISC.
- ANTICOAGULANTS
- ANTIPSYCHOTICS/ANTIMANIC AGENTS

Top Clinical Cost Drivers by Drug (2021):

- HUMIRA PEN (ANALGESICS - ANTI-INFLAMMATORY)
 - 2021 ingredient costs: \$973,486.29
 - 18 Utilizers (1 additional utilizers than 2020)
- TRULICITY (ANTIDIABETICS)
 - 2021 ingredient costs: \$899,243.92
 - 122 Utilizers (14 additional utilizers than 2020)
- OZEMPIC (ANTIDIABETICS)
 - 2021 ingredient costs: \$537,444.47
 - 109 Utilizers (48 additional utilizers than 2020)
- TREMFYA (DERMATOLOGICALS)
 - 2021 ingredient costs: \$476,054.15
 - 9 Utilizers (5 additional utilizers than 2020)
- JARDIANCE (ANTIDIABETICS)
 - 2021 ingredient costs: \$441,810.58
 - 101 Utilizers (12 additional utilizers than 2020)
- DUPIXENT (DERMATOLOGICALS)
 - 2021 ingredient costs: \$428,595.94
 - 17 Utilizers (4 additional utilizers than 2020)
- JANUVIA (ANTIDIABETICS)
 - 2021 ingredient costs: \$419,085.88
 - 118 Utilizers (11 additional utilizers than 2020)
- SPRYCEL (ANALGESICS - ANTI-INFLAMMATORY)
 - 2021 ingredient costs: \$371,137.92
 - 2 Utilizers (no change in utilization from 2020)

*Specialty medications require a prior authorization before they can be filled.

2020 Rebates:

- Q1 2021 net rebate amount is \$663, 828.00
- Q2 2021 net rebate amount is \$694, 892.00
- Q3 2021 net rebate amount is \$751,762

*Beginning with the fourth quarter of 2020, Rebates will be paid within 120 days at the end of the applicable quarter.

Clinical Management-

- Clinical Guarantee (18 months)- \$1,500,000
- Prorated Clinical Guarantee (Q3 2020-Q3 2021)- \$1,250,000
- Clinical Savings Performance (Q3 2020-Q3 2021)- \$5,349,933
- Clinical Overperformance- \$4,099,933

*Keenan performs a clinical savings financial audit and presents the final report to the SJVIA upon completion of the end of the plan year.

KPS Audit

KPS conducts a yearly financial audit of EmpiRx Clinical savings, Average Wholesale Price (AWP) discounts and Rebate performance against the client's aggregate contractual guarantees.